(Total Views: 647)
Posted On: 05/23/2021 6:45:27 PM
Post# of 153886
Hemispherix did not do the safety testing requested by the FDA, the requested length of trials or the requested patient population size.
administered by IV
Mechanism of action - TLR3 agonist which increases production of interferons and tumor necrosis factors. One of the safety studies requested by the FDA was for increased incidence of cancer. With an increase in unspecified interferons and tumor necrosis factor I can understand why.
Of note downstream it is purported to lower cytokines.
With no other drug FDA approved for Chronic Fatigue Syndrome it will be a wonderful opportunity for leronlimab after the longhaulers trials.
administered by IV
Mechanism of action - TLR3 agonist which increases production of interferons and tumor necrosis factors. One of the safety studies requested by the FDA was for increased incidence of cancer. With an increase in unspecified interferons and tumor necrosis factor I can understand why.
Of note downstream it is purported to lower cytokines.
With no other drug FDA approved for Chronic Fatigue Syndrome it will be a wonderful opportunity for leronlimab after the longhaulers trials.
(7)
(1)
